Skip to main content
. 2004 Mar 15;113(6):895–904. doi: 10.1172/JCI19852

Figure 7.

Figure 7

SAM therapy in fulminant hepatitis. Experimental ASMase+/+ mice (n = 40) were treated with Gal/LPS; control mice (Saline, in B; n = 40) were treated with saline. Mice were divided in three groups: one group received SAM (5 mg/mouse intraperitoneally) or saline every hour for 8 hours after treatment with Gal/LPS; in addition, half of the mice receiving SAM therapy were pretreated with BSO (4 mmol/kg). (A) Serum ALT or AST levels. *P < 0.05 versus Gal/LPS; #P < 0.05 versus ASMase+/+ mice treated with Gal/LPS + SAM. AST, aspartate aminotransferase. (B) Hematoxylin and eosin staining of livers with or without SAM administration or BSO treatment. Scale bars: 5 μm. (C) Hepatocellular SAM levels of ASMase+/+ mice challenged with Gal/LPS with or without SAM therapy. *P < 0.05 versus values at time 0; #P < 0.05 versus Gal/LPS group. (D) Caspase activity in livers from ASMase+/+ mice with or without SAM treatment. *P < 0.05 versus untreated mice; #P < 0.05 versus Gal/LPS group. (E) Hepatic GSH levels in ASMase+/+ mice with or without SAM treatment. *P < 0.05 versus values at time 0; #P < 0.05 versus Gal/LPS group. (F) Serum TNF-α levels in ASMase+/+ mice at various time points after Gal/LPS treatment with or without SAM therapy.